Ever since the discovery as a tumor suppressor for ARID1A, synthetic lethal phenotypes have been uncovered in ARID1A-deficient cells when treated with PARP inhibitors, ATR inhibitors, EZH2 inhibitors, and other emerging agents [13]. The gene discussed is ARID1A; the disease is neoplasm.